New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2014
09:04 EDTABBV, ENTA, DLLR, SLCA, IMGN, NOV, LYB, CYTR, TNP, CTXS, JDSU, TSN, MAT, MA, CMG, ZNGA, WMT, AMZN, GOOGOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Google (GOOG), up 4%... Chipotle (CMG), up 11.8%... JDSU (JDSU), up 6%... Tyson Foods (TSN), up 2.6%... ImmunoGen (IMGN), up 7%... LyondellBasell (LYB), up 2.4%... National-Oilwell Varco (NOV), up 1.8%. ALSO HIGHER: Zynga (ZNGA), up 18% after pre-announcing results, announcing job cuts and agreeing to buy privately-held NaturalMotion for about $527M... Citrix (CTXS), up 2% after upgrades at Nomura and JPMorgan... Enanta Pharmaceuticals (ENTA), up 15% after reporting on studies being conducted by AbbVie (ABBV) for the treatment of genotype 1 hepatitis C virus. DOWN AFTER EARNINGS: Amazon (AMZN), down 8%... Mastercard (MA), down 5.6%... Mattel (MAT), down 10%... U.S. Silica (SLCA), down 14%... DFC Global (DLLR), down 22.8%. ALSO LOWER: Wal-Mart (WMT), down xx% after warning now sees Q4 EPS at or slightly below low end of prior view.
News For GOOG;AMZN;WMT;ZNGA;CMG;MA;MAT;TSN;JDSU;CTXS;TNP;CYTR;LYB;NOV;IMGN;SLCA;DLLR;ENTA;ABBV From The Last 14 Days
Check below for free stories on GOOG;AMZN;WMT;ZNGA;CMG;MA;MAT;TSN;JDSU;CTXS;TNP;CYTR;LYB;NOV;IMGN;SLCA;DLLR;ENTA;ABBV the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>
August 7, 2014
18:10 EDTAMZNHachette drops bid for Perseus Books, reports WSJ
Subscribe for More Information
16:10 EDTZNGAZynga drops 13% to $2.55 after lowering 2014 outlook
Subscribe for More Information
16:10 EDTZNGAZynga says continues to make 'significant investments'
Subscribe for More Information
16:09 EDTZNGAZynga enters Sports category, signs agreement with Tiger Woods
Subscribe for More Information
16:08 EDTZNGAZynga reports Q2 monthly active users 130M vs. 187M last year
Zynga said Q2 Monthly Unique Payers in Q2 were 1.7M, compared to 1.9M last year. Daily active users in Q2 were 29M, compared to 39M last year. Monthly active users in Q2 were 130M, compared to 187M last year.
16:05 EDTZNGAZynga lowers 2014 EPS outlook to (1c)-0c, consensus 2c
Subscribe for More Information
16:04 EDTZNGAZynga sees Q3 EPS (1c)-0c, consensus 1c
Subscribe for More Information
16:03 EDTZNGAZynga reports Q2 EPS 0c, consensus 0c
Reports Q2 revenue $153.2M, consensus $191.2M. Generated bookings of $175M, adjusted EBITDA of $14M.
16:00 EDTZNGAOptions Update; August 7, 2014
Subscribe for More Information
15:33 EDTZNGA Notable companies reporting after market close
Subscribe for More Information
11:34 EDTTSNRussia retaliates with restrictions on U.S. chicken imports, CNN says
Subscribe for More Information
09:49 EDTAMZNAmazon readying to launch grocery service in New York area, Re/code says
Subscribe for More Information
09:36 EDTAMZNActive equity options trading on open
Subscribe for More Information
08:38 EDTENTAEnanta's HCV NS5A inhibitor EDP-239 advances into combination studies
Subscribe for More Information
07:27 EDTIMGNUBS to hold a conference
Subscribe for More Information
07:18 EDTLYBLyondellBasell management to meet with Deutsche Bank
Subscribe for More Information
06:36 EDTGOOG, AMZNGoogle, Barnes & Noble launching same-day book delivery service, NY Times says
Google (GOOG) and Barnes & Noble (BKS) today will begin allowing consumers in three cities to order books carried by Barnes & Noble stores and have them delivered to their homes on the same day, according to The New York Times. Users will order the books on Google Shopping Express, and the service will compete with Amazon, the newspaper stated. Reference Link
06:13 EDTGOOGGoogle to boost encrypted websites in rankings
Subscribe for More Information
06:06 EDTCYTRCytRx's aldoxorubicin for sarcomashows positive Phase 2b clinical trial results
CytRx's oral presentation titled “Randomized phase 2b trial comparing first-line treatment with aldoxorubicin versus doxorubicin in patients with advanced soft tissue sarcomas,” was featured in The Lancet Oncology in its July issue. The updated results from CytRx’s ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable STS demonstrated that aldoxorubicin significantly increases progression-free survival, PFS at 6 months, overall response rate and tumor shrinkage, compared to doxorubicin, the current standard-of-care, as a first-line treatment in patients with STS. The data trended in favor of aldoxorubicin for all of the major subtypes of STS. The company is on track to report the full overall survival results from this trial prior to year-end.
06:06 EDTCMGStocks with implied volatility below IV index mean; TWX CMG
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use